publications
FAQ

 

 
 
Forthcoming presentations
   

ADA, Washington 2006

Five poster presentations and one oral presentation of PROactive data will be given at the American Diabetes Association Annual Scientific Sessions that will be held 9-13 June 2006 in Washington, DC.

    • Wilcox R. Effects of Pioglitazone on Major Adverse Cardiovascular Events (MACE) and Myocardial Infarction: Results from PROactive (Oral Presentation Number: 317-OR)

    • Heine R et al. Long-Term Pioglitazone Treatment Improves Markers of Liver Function: Results from PROactive (Poster Presentation Number: 484-P)

    • Scheen A & Charbonnel B. Reduced Insulin Requirements and Improved Glycaemic Control with Pioglitazone in Insulin-Treated Patients with > Type 2 Diabetes:  Results from PROactive (Poster Presentation Number: 561-P)

    • Charbonnel B & Scheen A. Pioglitazone in Triple Oral Therapy: Long-Term Glycaemic Results from PROactive (Poster Presentation Number: 448-P)

    • Massi-Benedetti M et al. Pioglitazone Delays the Need for Permanent Insulin Use: Results from PROactive (Poster Presentation Number: 523-P)

    • Wilcox R et al. Effect of Pioglitazone in Stroke Prevention in Type 2 Diabetes: A Prespecified Subgroup Analysis of PROactive (Poster Presentation Number: 579-P)